The latest price target for Lineage Cell Therapeutics (AMEX:LCTX) was reported by D. Boral Capital on November 20, 2024. The analyst firm set a price target for $2.00 expecting LCTX to rise to within 12 months (a possible 233.33% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Lineage Cell Therapeutics (AMEX:LCTX) was provided by D. Boral Capital, and Lineage Cell Therapeutics maintained their buy rating.

There is no last upgrade for Lineage Cell Therapeutics

There is no last downgrade for Lineage Cell Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lineage Cell Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lineage Cell Therapeutics was filed on November 20, 2024 so you should expect the next rating to be made available sometime around November 20, 2025.

While ratings are subjective and will change, the latest Lineage Cell Therapeutics (LCTX) rating was a maintained with a price target of $3.00 to $2.00. The current price Lineage Cell Therapeutics (LCTX) is trading at is $0.60, which is out of the analyst’s predicted range.